Insecticides India Q1 - New Business Segments, R&D Investments To Be Key Growth Drivers: ICICI Securities
Insecticides India Q1 Review - New Business Segments, R&D Investments To Be Key Growth Drivers: ICICI Securities
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Insecticides India Ltd. reported strong revenue growth of 19.7% YoY in Q1 FY23, led by strong growth across geographies and market share gains (our view).
Ebitda margin was down 91 basis points YoY, despite gross margin expansion. Company was granted a new patent in July 2022 (after two in April 2022). These products will likely lead to higher margins in the medium to long term.
Insecticides has incorporated a subsidiary to foray into organic farming products. We remain positive on Insecticides India due to:
its focus on distribution expansion;
removal of generic products from the product portfolio and launch of differentiated products; and
backward integration of technicals.
We estimate an earnings compound annual growth rate of 16.5% over FY22-FY24E and return on equity to move to 13.7% in FY24E. We revise our FY23E-FY24E earnings to factor-in the Q1 FY23 performance and grant of new patents to the company.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.